New Report Analyses Big Data in Healthcare

Big Data in Healthcare

Medical data represents a large, rapidly growing, and mostly unstructured data residing in multiple locations including lab and imaging systems, physician notes, medical correspondence, claims, CRM and financial systems. With resizing costs with the healthcare industry, there is an imperative to reduce the cost of care and efficiently manage resources without compromising patient care. Healthcare organizations have the opportunity to leverage big data technology to perform analytics to improve care and profitability.

This report evaluates Big Data in healthcare ecosystem and opportunities including technologies, growth drivers, challenges, and stakeholders. The report analyzes different business models employed by healthcare big data business practices, including key factors affecting each business model, various company approaches and solutions.

Target Audience:

- Big Data application developers

- Telecommunications companies

- Big data management companies

- Healthcare institutions of all types

- Investors in Big Data infrastructure

Companies covered in this report are-

IBM, Oracle, Zanett, Explorys, Humedica, Predixion Software, Health Fidelity, Practice Fusion, Athenahealth Solutions, InterSystems, Pentaho, Verizon, Pervasive

Inquire about this report: Big Data in Healthcare

Medical Devices Market in India 2013

Medical Devices Market in India 2013

Medical devices market in India is expected to grow at a steady rate in the days to come. Increasing awareness towards healthcare, more budgetary allocation and increase in complex lifestyle disorders is likely to boost the demand of medical devices.

 

The report begins with macro economic indicators whereby the basic economic indicators have been depicted. In the introduction section the definition of medical devices as well as risk categories has been defined. In the market overview section the market size of the healthcare industry has been depicted. Thereby, the market size of the medical devices market has been forecasted. Major segments of medical devices and their relative share has been provided. Major segments of healthcare industry have been explained. Further the report depicts the division of refurbished and new medical equipments in the market and also the regional demand for medical devices. Market size of the major segments in medical equipment market has been calculated. In the next section import and export of medical devices for the last four years has been highlighted. Also the major countries for import and export for medical devices is also depicted. Thereafter, the distribution channel has been explained. 

To purchase and know more about this report visits: Medical Devices Market in India 2013

In the next section drivers and challenges has been highlighted. Drivers include improving health infrastructure which has caused the increased demand of medical devices from more number of hospitals/nursing homes, clinics and standalone pathology labs. Also, the government is spending more on healthcare needs which is supposed to increase demand of medical devices. As disposable income is increasing and more people are becoming aware of the diseases –spending towards healthcare segment is increasing. Also changing demographics i.e. as more people reach close to sixty years of age they are likely to develop some heart complications thus increasing the demand for medical devices. Increase in lifestyle diseases as well as huge boom in the medical tourism sector will see the market grow. Higher penetration of medical insurance will help people to go for operations helping the medical devices market to grow. Challenges in the market include high dependency on imports and lack of poor regulatory structure.

Trends include outsourcing of manufacturing facilities by some of the major international players in order to remain cost competitive and penetrate the Indian market. Increasing JVs and tie-ups with local players is also being adopted in the industry. Companies take part in various exhibitions and fairs to showcase their products. Also, there is a latent demand for refurbished products from various tier 2 hospitals and clinics. In order to maintain the leading edge manufacturers are focusing on cost reduction and innovation. It is in this attempt that they are using plastics in medical devices.  In the next section various government initiatives, rules and regulations have been highlighted. 

 

The competitive landscape section begins with a Porter’s five forces model which analyses the dynamics of the market. The major players in the market have been profiled which includes a financial summary for each of the players. Key ratios and key contacts are also listed. The last section offers strategic recommendations for the players in the cardiac pacemaker market. For each of the companies a SWOT analysis has been provided. In the following section recent investments in the medical devices industry has been listed. In the last section strategic recommendations has been provided which will be instrumental for the companies to garner a larger market share.

Companies Covered in this market research report : 

Public Companies

1. Opto Circuits India Ltd.
2. Siemens Ltd.

Private Companies

1. Allengers Medical Systems Ltd. 
2. Carestream Health India Pvt. Ltd. 
3. Fresenius Kabi India Pvt. Ltd. 
4. GE Medical Systems (India) Pvt. Ltd. 
5. HiMedia Laboratories Pvt. Ltd.
6. Philips Electronics India Ltd.
7. RFCL Ltd.
8. Roche Diagnostics India Pvt. Ltd.
9. Transasia Bio-Medicals Ltd.
10. Trivitron Healthcare Pvt. Ltd.
11. Vascular Concepts Ltd.

Laboratory Information Management System Market in India 2013

Laboratory Information Management System Market in India 2013

The Laboratory Information Management System (LIMS) forms a niche market segment in India presently. The growing systemization of laboratories will gradually steer forth the market. The simultaneous rapid development of Indian healthcare sector that is seeing rise in number of various types of laboratories will propel the future of LIMS adoption in Indian healthcare sector as well. The report begins with macro economic indicators whereby the basic economic indicators have been depicted.

 

The introduction section provides a broad overview of Indian healthcare sector and how IT adoption in healthcare is having a valued impact on performance of the sector. The report progresses to describe the sectors where LIMS has applications along with the benefits of the software. The section also describes the historical development pathway of LIMS.

To purchase and know more about this report please visit:   Laboratory Information Management System Market in India 2013

 

The next section highlights the value wise market size and growth of LIMS software and also the adoption of LIMS specifically in the Indian healthcare sector.

 

The report then describes the LIMS structure encapsulating common modules and the step wise workflow of the LIMS from requisition to information deliver and LIMS in terms of application. In the next section, the distribution channel has been elaborated from designing of software to final installation of software.

 

The report then focuses on the healthcare applications of LIMS with description of methodical solutions LIMS provides in life sciences, pharmaceutical and biotechnology and in contract service laboratories.

 

The next section elaborates the drivers and challenges that the market is currently facing. Drivers include growing clinical laboratories, growing pharmaceutical industry, growing clinical trials market, rising biotechnology industry and factor such as significance laid on laboratory accreditation. Challenges in the market include disparity in ‘quality’ standards and high cost of installation.

 

Though the LIMS market is still in a nascent stage, yet the software developers are trying to make the software user friendly and cost effective for which it has come up with the concept of LIMS on Cloud.

 

The competitive landscape section begins with the Porter’s Five Forces Analysis, illustrating the competitive rivalry, bargaining power of suppliers and buyers and threat of new entrants and substitutes. The section includes competitive benchmarking of the top players operating in the Indian LIMS market. The report also features brief profiles of major domestic and foreign players in the market and a snapshot of their corporation, financial performance along with the key financial ratios, business highlights, their product portfolio and SWOT analysis, thus providing an insight into the existing competitive scenario.

 

The final section of the report contains strategic recommendations which will be instrumental for the companies to garner a larger market share in the Indian market.

Companies Covered in this market research report : 

Public Companies

1. Persistent Systems Ltd.

Private Companies

1. Agilent Technologies India Pvt. Ltd.
2. Birlamedisoft Pvt. Ltd.
3. Caliber Technologies Pvt. Ltd.  
4. Labvantage Solutions Pvt. Ltd.
5. Oasis Infotech Ltd.
6. Ocimum Biosolutions (India) Ltd.
7. Perkinelmer (India) Pvt. Ltd.
8. STARLIMS Asia Pacific Ltd.
9. Sukraa Software Solution Pvt. Ltd.
10. Thermo Fisher Scientific India Pvt. Ltd.

Dengue Fever Partnering 2007-2013

Dengue Fever Partnering 2007-2013

The Dengue Fever Partnering  2007-2013 provides understanding and access to the dengue fever partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides an analysis of dengue fever partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors dengue fever technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

 

This data driven report contains over 30 links to online copies of actual dengue fever deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of  dengue fever partnering trends.

 

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in  dengue fever partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

 

Chapter 3 provides an overview of the leading dengue fever deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive directory of  dengue fever partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the

research, development and commercialization of  dengue fever technologies and products.

 

Report scope

 

Dengue Fever Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to  dengue fever trends and structure of deals entered into by leading companies worldwide.

 

This data driven report includes:

 

Trends in  dengue fever dealmaking in the biopharma industry since 2007 

Access to summary headline, upfront, milestone and royalty data 

The leading  dengue fever deals by value since 2007 

 

In Dengue Fever Partnering 2007-2013, the available deals are listed by:

 

• Headline value 
• Upfront payment value 
• Royalty rate value 
• Company A-Z 
• Industry sector 
• Stage of development at signing 
• Deal component type 
• Technology type 
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Nutrition and Vitamin Partnering 2007-2013

Nutrition and Vitamin Partnering 2007-2013

Nutrition & Vitamins Partnering  2007-2013 provides understanding and access to the nutrition & vitamins partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides an analysis of nutrition & vitamins partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors nutrition & vitamins technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

 

This data driven report contains over 220 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of nutrition & vitamins partnering trends.

 

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in nutrition & vitamins partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

 

Chapter 3 provides an overview of the leading nutrition & vitamins deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive directory of nutrition & vitamins partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the

research, development and commercialization of nutrition & vitamins technologies and products.

 

Report scope

 

Nutrition & Vitamins Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to nutrition & vitamins trends and structure of deals entered into by leading companies worldwide.

 

This data driven report includes:

 

Trends in nutrition & vitamins dealmaking in the biopharma industry since 2007 

Access to summary headline, upfront, milestone and royalty data 

The leading nutrition & vitamins deals by value since 2007 

 

In Nutrition & Vitamins Partnering 2007-2013, the available deals are listed by:

 

• Headline value 
• Upfront payment value 
• Royalty rate value 
• Company A-Z 
• Industry sector 
• Stage of development at signing 
• Deal component type 
• Technology type 
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Liver Disease Partnering 2007-2013

Liver Disease Partnering 2007-2013

Liver Disease Partnering  2007-2013 provides understanding and access to the liver disease partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides an analysis of liver disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors liver disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

 

This data driven report contains over 50 links to online copies of actual liver disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of liver disease partnering trends.

 

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in liver disease partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

 

Chapter 3 provides an overview of the leading liver disease deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive directory of liver disease partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the

research, development and commercialization of liver disease technologies and products.

 

Report scope

 

Liver Disease Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to liver disease trends and structure of deals entered into by leading companies worldwide.

 

This data driven report includes:

 

Trends in liver disease dealmaking in the biopharma industry since 2007 

Access to summary headline, upfront, milestone and royalty data 

The leading liver disease deals by value since 2007 

 

In Liver Disease Partnering 2007-2013, the available deals are listed by:

 

• Headline value 
• Upfront payment value 
• Royalty rate value 
• Company A-Z 
• Industry sector 
• Stage of development at signing 
• Deal component type 
• Technology type 
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

Liver Disease Partnering 2007-2013 provides the reader with the following key benefits:

 

• In-depth understanding of liver disease deal trends since 2007 
• Access to summary headline, upfront, milestone and royalty data 
• Comprehensive access to over 50 actual liver disease deals entered into by the world’s biopharma companies since 2007 
• Insight into key deal terms included in contracts, where disclosed 
• Understand the key deal terms companies have agreed in deals 
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies 

Diabetes Partnering 2007-2013

Diabetes Partnering 2007-2013

The Diabetes Partnering  2007-2013 provides understanding and access to the diabetes partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides an analysis of diabetes partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors diabetes technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

 

This data driven report contains over 500 links to online copies of actual diabetes deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of diabetes partnering trends.

 

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in diabetes partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

 

Chapter 3 provides an overview of the leading diabetes deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive directory of diabetes partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the

research, development and commercialization of diabetes technologies and products.

 

Report scope

 

Diabetes Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to diabetes trends and structure of deals entered into by leading companies worldwide.

 

This data driven report includes:

 

Trends in diabetes dealmaking in the biopharma industry since 2007 

Access to summary headline, upfront, milestone and royalty data 

The leading diabetes deals by value since 2007 

 

In Diabetes Partnering 2007-2013, the available deals are listed by:

 

• Headline value 
• Upfront payment value 
• Royalty rate value 
• Company A-Z 
• Industry sector 
• Stage of development at signing 
• Deal component type 
• Technology type 
• Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Arthritis Partnering 2007-2013

Arthritis Partnering 2007-2013

Arthritis Partnering 2007-2013 report provides understanding and access to the arthritis partnering deals and agreements entered into by the worlds leading healthcare companies.

 

Trends in arthritis partnering deals

Top arthritis deals by value

Deals listed by company A-Z, industry sector, stage of development, technology type

 

Arthritis Partnering 2007-2013 provides understanding and access to the arthritis partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides an analysis of arthritis partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors arthritis technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

 

This data driven report contains over 260 links to online copies of actual arthritis deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of arthritis partnering trends.

 

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in arthritis partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

 

Chapter 3 provides an overview of the leading arthritis deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive directory of arthritis partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of arthritis technologies and products.

 

Report scope

 

Arthritis Partnering 2007-2013 is intended to provide the reader with an in-depth understanding and access to arthritis trends and structure of deals entered into by leading companies worldwide.

 

This data driven report includes:

 

Trends in arthritis dealmaking in the biopharma industry since 2007

Access to summary headline, upfront, milestone and royalty data

The leading arthritis deals by value since 2007

 

In Arthritis Partnering 2007-2013, the available deals are listed by:

 

• Headline value
• Upfront payment value
• Royalty rate value
• Company A-Z
• Industry sector
• Stage of development at signing
• Deal component type
• Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Metabolic Partnering Terms and Agreements

Metabolic Partnering Terms and Agreements

The Metabolic Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the metabolic partnering deals and agreements entered into by the worlds leading healthcare companies.

 

The report provides a detailed understanding and analysis of how and why companies enter metabolic partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors metabolic technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

 

This report contains over 1,000 links to online copies of actual metabolic deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of metabolic dealmaking and business activities. Chapter 1 provides an introduction to the report.

 

Chapter 2 provides an overview of the trends in metabolic dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

 

Chapter 3 provides a review of the leading metabolic deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of metabolic deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides comprehensive access to all metabolic deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive directory of all metabolic partnering deals signed and announced since 2007. The chapter is organized by specific metabolic therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

In addition, a comprehensive appendix is provided with each report of all metabolic partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in metabolic partnering and dealmaking since 2007.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of metabolic technologies and products.